iLet® ACE Pump (Beta Bionics): Safety Alerts, FDA Warning Letter, and What Patients Should Watch For

June 02, 202610 minute read

Published by Justpoint Inc.

If you use the iLet® Bionic Pancreas — the automated insulin-delivery system that pairs the iLet® ACE Pump with the iLet® Dosing Decision Software, manufactured by Beta Bionics, Inc. — three independent safety signals have converged in the past two years and deserve your attention.

The U.S. Food and Drug Administration (FDA) inspected Beta Bionics’ Irvine, California, manufacturing facility from June 9 through June 26, 2025, and on January 28, 2026 sent the company a Warning Letter (MARCS-CMS 717927) citing multiple violations of medical-device quality-system and reporting regulations.
The FDA’s Warning Letter records approximately 529 patient complaints of leaking insulin cartridges or cartridge connectors between June 2023 and June 2025, and 107 serious-injury complaints describing severe hypoglycemia or events requiring medical intervention to prevent severe hypoglycemia. Complaint and Medical Device Report (MDR) data reflect reported associations and are subject to reporting and selection bias; they do not establish that the device caused the reported event.
The pump had a cybersecurity vulnerability affecting its “Limited Access” passcode/lockscreen feature that allowed an unauthorized user to change settings — including stopping insulin delivery or giving inappropriate boluses — without entering the passcode. Beta Bionics released a software fix (Version 1.4.3) on March 26, 2024, and e-mailed customers on April 1, 2024, but the FDA later concluded the company had not properly reported the correction.

This article explains what the device is, what regulators have found, what symptoms and malfunctions to watch for, and how to confirm whether your specific pump is affected. It is written for patients, families, and clinicians — not for legal action.

What the iLet® ACE Pump is

The iLet® ACE Pump is the durable insulin-pump hardware component of the iLet® Bionic Pancreas System developed by Beta Bionics, Inc. (Irvine, California, with original operations in Concord, Massachusetts). It is paired with a separate algorithm — the iLet® Dosing Decision Software — and a continuous glucose monitor (CGM), and together the three pieces form an automated insulin-delivery (AID) system intended for people aged six years and older living with type 1 diabetes.

The pump itself is regulated by the FDA as an Alternate Controller Enabled (ACE) insulin infusion pump, product code QFG. The dosing software is regulated separately as an Interoperable Automated Glycemic Controller (iAGC), product code QJI. Both received FDA 510(k) clearance on May 19, 2023 under premarket notification number K223846. Both are classified as Class II medical devices, meaning they are moderate-risk and were authorized through the FDA’s “substantial equivalence” pathway rather than a full premarket approval (PMA) clinical trial.

The “ACE” designation is important: it means the pump is designed to be used with multiple compatible iAGCs and CGMs, not just Beta Bionics’ own software. In practice most iLet users today run the Beta Bionics dosing algorithm paired with a Dexcom or Abbott FreeStyle Libre CGM.

The hardware model identified by the FDA in inspection records is iLet Bionic Pancreas Model TA000036.

The three safety signals, in plain language

1. Cartridge and connector leaks — risk of under-delivery and high blood sugar

The iLet ACE Pump uses a disposable insulin cartridge and tubing that connects the cartridge to an infusion set on the body. Between June 2023 and June 2025, Beta Bionics received roughly 529 complaints of leaking cartridges or cartridge connectors while the device was in use. When insulin leaks out of the system instead of being delivered into the body, the user receives less insulin than the pump records — which may result in hyperglycemia (high blood sugar) and, in severe cases, diabetic ketoacidosis (DKA), a medical emergency that can require hospitalization.

The FDA cited Beta Bionics for closing 31 of those leak complaints without an investigation, including 18 in which the patient reported a hyperglycemic health effect. The FDA Warning Letter characterizes this as a complaint-investigation procedural deficiency: per FDA findings, complaints involving reported patient harm were closed without documented root-cause investigation.

2. Severe hypoglycemia events — risk of seizure, loss of consciousness, or worse

The FDA also recorded 107 complaints submitted as serious-injury reports describing severe hypoglycemia (very low blood sugar) or events where medical intervention was required to prevent severe hypoglycemia. According to the Warning Letter, FDA records indicate 56 of those complaints were closed without documented corrective actions.

Severe hypoglycemia in an insulin-pump user can be serious because the user may not feel the symptoms in time. If untreated, very low blood sugar may lead to shakiness, sweating, confusion, slurred speech, seizure, loss of consciousness, or death.

Two specific failure modes appear repeatedly in the inspection record:

Over-infusion from involuntary “meal announcements.” The iLet algorithm normally responds when the user announces a meal, but inspectors found at least two complaints in which an over-infusion of insulin followed an involuntary meal announcement, associated with severe hypoglycemia. Beta Bionics traced this to delayed glucose readings being sent from the CGM supplier and applied a temporary software change on April 5, 2024 while the CGM supplier rolled out a permanent fix.
Printed-circuit-board (PCBA) failures. Complaints from October 2024 through June 2025 reported malfunctions of the iLet Bionic Pancreas Model TA000036 associated with failure of the printed-circuit-board assembly supplied by a third party. According to FDA inspection findings, 19 customer complaints were associated with PCBA mainboards with improperly installed components.

3. Cybersecurity vulnerability in “Limited Access” mode

The iLet has a “Limited Access” passcode/lockscreen feature meant to keep someone other than the user — for example, a child or a stranger — from changing pump settings. Beta Bionics found cases in which the lockscreen or Limited Access passcode screen was displayed, certain other icons remained active and tappable. That meant an unauthorized person could still change settings, including stopping insulin delivery or giving inappropriate boluses, without entering the passcode. Either action may result in hyperglycemia or severe hypoglycemia.

Beta Bionics released Software Version 1.4.3 on March 26, 2024 to close the vulnerability, and e-mailed all customers on April 1, 2024 with a notice titled “iLet Software Update.” The FDA’s later inspection determined the company should have reported the action to the agency as a correction under 21 CFR 806.10, and the company’s failure to do so became one of the cited violations in the Warning Letter.

What the FDA Warning Letter says

The FDA’s Warning Letter (MARCS-CMS 717927, issued January 28, 2026 and posted publicly in late February 2026) cites multiple deficiencies, in plain summary:

Medical Device Reporting (MDR) timeliness. Several individual MDRs were submitted past the 30-calendar-day deadline required by 21 CFR 803.50(a), and at least two complaints (one from April 2024 and one from June 2024) had not been reported to the FDA at all by the time of the inspection.
Inadequate complaint investigation. Many cartridge/connector-leak and serious-injury complaints were closed without root-cause investigation.
Unreported corrections. The cybersecurity Limited-Access software fix and the temporary meal-announcement software change were not reported to the FDA as required under 21 CFR 806.10.
Risk-analysis gaps. The company’s System Risk Analysis did not adequately incorporate post-market risks identified through complaint data.
CAPA (corrective and preventive action) deficiencies. Procedures and follow-through were judged inadequate.

Beta Bionics has stated publicly that it does not expect the Warning Letter to affect its ability to manufacture, market, or distribute the iLet system. The system remains on the U.S. market as of this writing, and the company has begun remediation work in response to the FDA.

What the published clinical evidence shows

Automated insulin-delivery systems as a category have been studied in multiple recent systematic reviews and meta-analyses. Two representative 2024–2025 reviews:

Steiman de Visser et al., JAMA Pediatrics (2025). Systematic review and meta-analysis of randomized trials of AID systems in children and adolescents with type 1 diabetes. PMID: 40920375. The pooled estimate showed a roughly +11.5% improvement in time-in-range and a −0.41% reduction in HbA1c versus other insulin regimens; the authors reported no statistically significant difference in adverse events between AID and comparator arms.
Fan et al., Diabetes & Metabolism Journal (2025). Systematic review and meta-analysis of randomized trials of AID systems in adults with type 1 diabetes. PMID: 39533812. Pooled time-in-range improvement was +11.74%; the authors found AID systems generally favorable for hypoglycemia reduction, particularly in patients with longer disease duration.

An internal source dataset referenced an unsourced odds-ratio figure (approximately 15.48 for any adverse event versus standard care) attributed to the iLet platform. Because we cannot trace that specific figure to a publicly indexed systematic review or meta-analysis, it has been removed from this article rather than presented with a caveat.

Who is at higher risk

The FDA inspection findings do not single out a specific patient demographic. Based on the failure modes identified, however, the practical risk picture is:

Users who rely on the pump unattended for long stretches (overnight, during exercise, during work) are most exposed to a silent leak or a quiet over-infusion event.
Children, older adults, and people with hypoglycemia unawareness are most likely to experience harm from a severe-hypoglycemia event before they can intervene.
Caregivers who use the Limited Access mode to keep a child or a confused adult from changing settings should be aware of the historical vulnerability and confirm their pump is running the patched software.

Warning signs to monitor

Some symptoms of severe hypoglycemia (low blood sugar)

Shakiness, sweating, racing heart, hunger
Dizziness, blurred vision, slurred speech
Confusion, irritability, or unusual behavior
Seizure or loss of consciousness — call 911

Some symptoms of severe hyperglycemia or DKA (high blood sugar)

Excessive thirst and frequent urination
Persistent fatigue, blurred vision
Nausea, vomiting, abdominal pain
Fruity-smelling breath, deep or rapid breathing — call 911

Mechanical signs from the pump

Visible insulin leak around the cartridge, connector, or tubing
Wet, damp, or oily skin around the infusion site
Persistent or unfamiliar alarm error codes
Pump display not matching the dose you intended

Unexpected pump behavior

Boluses you did not initiate
Settings that have changed without your input
Insulin delivery suddenly stopped or paused while the pump is unlocked
Anything that suggests the Limited Access lockscreen is not behaving as designed

If any of these occur, treat the immediate blood-sugar problem first, then contact and/or follow up with your healthcare provider.

Three ways to confirm which pump you have

Your pump labeling and serial number. The model identifier (e.g., TA000036) and serial number are printed on the back of the device or shown in the device’s settings/About screen. Compare this with any safety notice you receive from Beta Bionics.
Beta Bionics Support. Beta Bionics offers 24/7 customer support at 1-855-745-3800 and online at betabionics.com/support. Support can verify your device model, your current software version, and whether your pump has received the cybersecurity-related software update.
Your prescribing clinician’s record. Your endocrinologist or certified diabetes-care and -education specialist (CDCES) typically has the device model, serial number, and prescription date in the chart. Ask specifically: “What model and serial number is on file, and is my software up to date?”

What to do if you are using one now

You do not need to stop using the iLet on the basis of the FDA Warning Letter alone — the device is still on the U.S. market and many users continue to benefit from automated dosing. But several practical steps make sense:

Confirm your software version. Open the pump’s About / Information screen, or ask Beta Bionics support or your endocrinologist or your healthcare provider to confirm whether an update applies to your specific pump.
Inspect your cartridge and tubing daily. Look for any sign of leakage, dampness, or unexplained skin moisture near the infusion site. Even a small leak can mean dose loss.
Discuss hypoglycemia and hyperglycemia/DKA preparedness with your healthcare provider. Diabetes-care guidelines commonly recommend keeping fast-acting carbohydrates available for hypoglycemia and reviewing a plan for hyperglycemia or DKA symptoms with your clinician.
Monitor your CGM closely after meals and overnight. The over-infusion failure mode that the FDA flagged was linked to delayed CGM readings. If your CGM and pump appear out of sync, consider confirming your glucose with a manual finger-stick reading and contact your care team if needed.
Ask your clinician whether a glucagon emergency kit is appropriate for you. Glucagon nasal spray or injection is sometimes prescribed for severe hypoglycemia situations where a person cannot swallow; whether this is right for you is a discussion to have with your prescriber.
Talk to your doctor or diabetes care clinician. Bring this article, the FDA Warning Letter URL, and any device-related symptoms you have noticed to your next appointment.

Reporting a problem to the FDA

Anyone — patient, caregiver, or clinician — can report a problem with the iLet directly to the FDA’s MedWatch adverse-event reporting program. Patient reports add to the data the FDA uses to monitor device safety in the real world:

Online: www.fda.gov/medwatch
Phone: 1-800-FDA-1088 (1-800-332-1088)

A MedWatch report is not a lawsuit and does not commit you to any legal action. It is a public-health safety report.

Regulatory and legal context

The iLet has not been the subject of a Class I (most-serious) recall as of this writing. The two Class 2 device-recall entries on file in the FDA database for the iLet ACE Pump (FDA recall IDs 218863 and 218989) relate to corrections rather than market withdrawals. The system remains commercially available. The combination of the January 2026 Warning Letter, the 529 leak complaints, the 107 serious-injury complaints, and the historical Limited-Access cybersecurity correction together represent significant ongoing regulatory scrutiny, but not a market-withdrawal event.

Insulin pumps from other manufacturers — including Medtronic MiniMed 600-series models and Tandem t:slim X2 pumps — have been the subject of separate FDA recalls and patient injury reports in recent years. The current Beta Bionics situation is its own regulatory matter; it is mentioned here only so that users do not confuse one company’s actions with another’s.

Check if you qualify

Contact Us

[email protected]

If you are researching this device, these related Justpoint patient guides may also be relevant:

Omnipod 5 Pods Recall: Internal Tubing Tear, Insulin Leakage, and What to Do — Omnipod 5 — another automated insulin-delivery pump with a 2026 Class I recall
True Metrix Blood Glucose Monitoring Systems: The E-5 Error Code, the 2026 Class I Recall, and What Patients Need to Know — True Metrix blood-glucose meters — used by many insulin-pump users for backup monitoring

Sources and how to verify

FDA Warning Letter to Beta Bionics, Inc. — MARCS-CMS 717927, January 28, 2026. Available at www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beta-bionics-inc-717927-01282026. Cites inspection of the Irvine, California facility from June 9 through June 26, 2025; documents 529 cartridge/connector-leak complaints, 107 serious-injury complaints (severe hypoglycemia or requiring medical intervention), Limited-Access lockscreen vulnerability and Software Version 1.4.3 fix (released 3/26/2024, customer notification 4/1/2024), and unreported corrections under 21 CFR 806.10.
FDA 510(k) clearance K223846, Beta Bionics, Inc., decision date May 19, 2023. Searchable at accessdata.fda.gov. Pump product code QFG (ACE insulin infusion pump); software product code QJI (interoperable automated glycemic controller); both Class II.
FDA Class 2 device-recall records for the iLet ACE Pump and iLet ACE Pump / Dosing Decision Software — FDA recall IDs 218863 and 218989, both indexed in the FDA recall database at accessdata.fda.gov/scripts/cdrh/cfdocs/cfres.
Steiman de Visser H, et al. “Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis.” JAMA Pediatrics (2025). PMID: 40920375. DOI: 10.1001/jamapediatrics.2025.2740.
Fan W, et al. “Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes & Metabolism Journal (2025). PMID: 39533812. DOI: 10.4093/dmj.2024.0130.
Beta Bionics customer support: 24/7 at 1-855-745-3800; web: betabionics.com/support.
FDA MedWatch adverse-event reporting: www.fda.gov/medwatch or 1-800-FDA-1088.

This article was published by Justpoint Inc. The information provided is for educational purposes, does not constitute medical or legal advice and is based on publicly available research and regulatory communications. Findings may vary depending on individual circumstances, device type, and clinical context. If you have a medical device that may be affected, please consult your physician. If you believe you may have a legal claim, please consult a qualified attorney.

Justpoint Inc. supports Justpoint Law (Justpoint PLLC) by providing operational and administrative services. All legal services are provided by Justpoint Law, and any client-related communications are made on its behalf.

Share this article